{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Blood&page=33",
    "query": {
      "condition": "Blood",
      "page": 33
    },
    "page_size": 10
  },
  "pagination": {
    "page": 33,
    "page_size": 10,
    "total_count": 13518,
    "total_pages": 1352,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Blood&page=34&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Blood&page=32&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-28T23:43:30.081Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02431312",
      "title": "Phase I Study of INO-1800 With or Without INO-9112 + EP in Chronic Hepatitis B Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hepatitis B"
      ],
      "interventions": [
        {
          "name": "INO-1800",
          "type": "BIOLOGICAL"
        },
        {
          "name": "INO-9112",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Nucleos(t)ide Analogue Treatment",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Inovio Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 90,
      "start_date": "2015-01-12",
      "completion_date": "2018-05-22",
      "has_results": false,
      "last_update_posted_date": "2019-10-15",
      "last_synced_at": "2026-10-28T23:43:30.081Z",
      "location_count": 7,
      "location_summary": "San Diego, California • Miami, Florida • Manhasset, New York + 4 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Manhasset",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02431312"
    },
    {
      "nct_id": "NCT00001628",
      "title": "The Role of Angiotensin Type I Receptor in the Regulation of Human Peripheral Vascular Function",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Atherosclerosis",
        "Heart Failure, Congestive",
        "Hypertension",
        "Myocardial Infarction"
      ],
      "interventions": [
        {
          "name": "Angiotensin II type 1 receptor antagonists",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 36,
      "start_date": "1997-07",
      "completion_date": "2000-09",
      "has_results": false,
      "last_update_posted_date": "2008-03-04",
      "last_synced_at": "2026-10-28T23:43:30.081Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00001628"
    },
    {
      "nct_id": "NCT01779167",
      "title": "Thalidomide, Lenalidomide, and Rituximab for Previously Treated Waldenstrom Macroglobulinemia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Waldenstrom Macroglobulinemia"
      ],
      "interventions": [
        {
          "name": "Thalidomide",
          "type": "DRUG"
        },
        {
          "name": "Lenalidomide",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Weill Medical College of Cornell University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 4,
      "start_date": "2012-06",
      "completion_date": "2014-04",
      "has_results": true,
      "last_update_posted_date": "2018-07-11",
      "last_synced_at": "2026-10-28T23:43:30.081Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01779167"
    },
    {
      "nct_id": "NCT04663100",
      "title": "Oral Adherence in Hematological Oncology Agents and Impact on Comorbid Therapy Adherence",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Chronic Myeloid Leukemia",
        "Chronic Lymphocytic Leukemia",
        "Multiple Myeloma",
        "Multiple Chronic Conditions"
      ],
      "interventions": [
        {
          "name": "Patient-reported outcome measure",
          "type": "OTHER"
        },
        {
          "name": "Comprehensive Medication Review",
          "type": "OTHER"
        },
        {
          "name": "Pharmacist communication",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of Tennessee",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2021-02-08",
      "completion_date": "2023-12-31",
      "has_results": false,
      "last_update_posted_date": "2023-12-04",
      "last_synced_at": "2026-10-28T23:43:30.081Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04663100"
    },
    {
      "nct_id": "NCT03961009",
      "title": "Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in PID Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Primary Immunodeficiency Disease"
      ],
      "interventions": [
        {
          "name": "Kedrion IVIG 10%",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Kedrion S.p.A.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "2 Years to 70 Years"
      },
      "enrollment_count": 47,
      "start_date": "2019-04-30",
      "completion_date": "2020-12-21",
      "has_results": true,
      "last_update_posted_date": "2026-05-05",
      "last_synced_at": "2026-10-28T23:43:30.081Z",
      "location_count": 11,
      "location_summary": "North Palm Beach, Florida • Chicago, Illinois • Overland Park, Kansas + 7 more",
      "locations": [
        {
          "city": "North Palm Beach",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Overland Park",
          "state": "Kansas"
        },
        {
          "city": "Plymouth",
          "state": "Minnesota"
        },
        {
          "city": "Little Silver",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03961009"
    },
    {
      "nct_id": "NCT03835299",
      "title": "Addressing Fear and Risk of Vasovagal Reactions Among High School Donors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Blood Donors"
      ],
      "interventions": [
        {
          "name": "Fear Intervention",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Ohio University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 4035,
      "start_date": "2019-02-15",
      "completion_date": "2020-01-15",
      "has_results": false,
      "last_update_posted_date": "2021-09-16",
      "last_synced_at": "2026-10-28T23:43:30.081Z",
      "location_count": 1,
      "location_summary": "Athens, Ohio",
      "locations": [
        {
          "city": "Athens",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03835299"
    },
    {
      "nct_id": "NCT01993706",
      "title": "Study of the Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-HIVMAB060-00-AB (VRC01), Administered Intravenously or Subcutaneously to Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infection",
        "Monoclonal Antibody, Human",
        "HIV Antibodies",
        "VRC01 Monoclonal Antibody",
        "Neutralizing Antibody"
      ],
      "interventions": [
        {
          "name": "VRC-HIVMAB060-00-AB",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 29,
      "start_date": "2013-11-19",
      "completion_date": "2015-02-27",
      "has_results": false,
      "last_update_posted_date": "2019-12-17",
      "last_synced_at": "2026-10-28T23:43:30.081Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01993706"
    },
    {
      "nct_id": "NCT00002107",
      "title": "A Phase I Study of Subcutaneously Administered Proleukin (Aldesleukin) in HIV-Infected Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Aldesleukin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Chiron Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2005-06-24",
      "last_synced_at": "2026-10-28T23:43:30.081Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00002107"
    },
    {
      "nct_id": "NCT00028236",
      "title": "Stem Cell Gene Therapy to Treat X-Linked Severe Combined Immunodeficiency (XSCID)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Severe Combined Immunodeficiency"
      ],
      "interventions": [
        {
          "name": "Gene-Transduced Autologous CD34+ Stem Cells",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Months",
        "maximum_age": "20 Years",
        "sex": "ALL",
        "summary": "18 Months to 20 Years"
      },
      "enrollment_count": 3,
      "start_date": "2001-12-10",
      "completion_date": "2011-07-25",
      "has_results": false,
      "last_update_posted_date": "2017-07-02",
      "last_synced_at": "2026-10-28T23:43:30.081Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00028236"
    },
    {
      "nct_id": "NCT00006436",
      "title": "EPOCH and Rituximab to Treat Non-Hodgkin's Lymphoma in Patients With HIV Infection",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lymphoma, AIDS-related",
        "Lymphoma, Large B-Cell, Diffuse"
      ],
      "interventions": [
        {
          "name": "Rituximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "EPOCH",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 68,
      "start_date": "2001-01-29",
      "completion_date": "2024-01-18",
      "has_results": true,
      "last_update_posted_date": "2026-08-03",
      "last_synced_at": "2026-10-28T23:43:30.081Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00006436"
    }
  ]
}